3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
2
Terminated
1
Sponsor Class
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Colorectal Neoplasms
56
Carcinoma, Non-Small-Cell Lung
35
Breast Neoplasms
29
Neoplasm Metastasis
23
Glioblastoma
23
Colonic Neoplasms
23
Rectal Neoplasms
19
Ovarian Neoplasms
16
Neoplasms
15
Brain Neoplasms
12
Lung Neoplasms
11
Pancreatic Neoplasms
10
Glioma
10
Fallopian Tube Neoplasms
10
Carcinoma, Renal Cell
10
Carcinoma, Hepatocellular
9
Gliosarcoma
7
Adenocarcinoma of Lung
7
Kidney Neoplasms
6
Liver Neoplasms
5
Astrocytoma
5
Sarcoma
4
Recurrence
4
Oligodendroglioma
4
Melanoma
4
Uterine Cervical Neoplasms
3
Lymphoma, Non-Hodgkin
3
Leukemia, Myeloid, Acute
3
Triple Negative Breast Neoplasms
2
Thyroid Neoplasms
2
Interventions
Imatinib Mesylate
10
Sunitinib
4
spartalizumab
2
pembrolizumab
2
nilotinib
2
Surveys and Questionnaires
2
tanespimycin
1
ribociclib
1
pexidartinib
1
pazopanib
1
olaratumab
1
oblimersen
1
motexafin lutetium
1
masitinib
1
guadecitabine
1
ferric carboxymaltose
1
famitinib
1
epacadostat
1
Surgical Procedures, Operative
1
Quality of Life
1
Observation
1
Iron-Dextran Complex
1
Indocyanine Green
1
Immunoglobulin G
1
Fluorescein
1
Disulfides
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Gastrointestinal Stromal Tumors
×
Bevacizumab
×
Clear all
NCT00324987
2017-09-14
S0502
National Cancer Institute (NCI)
Phase 3
Terminated
12 enrolled
13 charts